Tony Yao, M.D., Ph.D. is the Portfolio Manager for ArrowMark’s life science strategy. Tony graduated magna cum laude from Brown University with a bachelor’s degree in Biochemistry and earned both an M.D. and Ph.D. in Immunology from Stanford University.
Life Science Strategy
Our Life Science strategy draws upon the extensive scientific backgrounds and investment experience of ArrowMark’s life science team, led by Dr. Tony Yao, M.D. and Ph.D. to identify pre-IPO and early stage public life science companies focused on advancing novel therapeutic agents and drug discovery/research technologies aimed at improving the standard of medical care and quality of patient life.
Adhering to a science-driven investment philosophy and fundamental research process, the strategy pursues a multi-stage investment approach, seeking to provide strategic guidance and long-term, value-added capital throughout a company’s clinical development path.
Allan Wong, Ph.D. is an Investment Analyst at ArrowMark Partners. Prior to joining ArrowMark, Allan was a Project Scientist at the Janelia Research Campus of the Howard Hughes Medical Institute, where he led two teams in neuroscience. Allan received his bachelor’s degree from UC Berkeley and Ph.D. from Columbia University working in the lab of Dr. Richard Axel, Nobel Laureate 2004.
Matt Eckler, Ph.D. is an Investment Analyst at ArrowMark Partners. Matt graduated from the University of North Carolina at Chapel Hill with a bachelor’s degree in Biology and earned his Ph.D. in Molecular, Cell, and Developmental Biology from the University of California, Santa Cruz.